

Setrusumab

Cat. No.:	HY-P99398
CAS No.:	1847394-95-9
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Setrusumab (BPS 804) is a fully human monoclonal antibody targets sclerostin. Setrusumab efftively improves bone strength. Setrusumab can be used for the reserch of Osteogenesis Imperfecta (OI) and cancer ^[1] .								
In Vivo	<p>Setrusumab (100 mg/kg; i.v. once a week for 4 weeks) inhibits breast cancer-induced bone metastases and muscle weakness in mice^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>8-week-old female immune-compromised CB-17/lcr-Prkdc^{scid}/Rj mice with MDA-MB-231 breast cancer cells injection^[1]</td> </tr> <tr> <td>Dosage:</td> <td>100 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection; 100 mg/kg once a week for 4 weeks</td> </tr> <tr> <td>Result:</td> <td>Significantly inhibited tumor growth in bones and breast cancer cell dissemination into other organs. Inhibited breast cancer-induced osteolytic lesions and subsequent loss of bone mass of the distal femur and of the proximal tibia. Redued phosphorylation of IKKα, IKKβ, and p65.</td> </tr> </table>	Animal Model:	8-week-old female immune-compromised CB-17/lcr-Prkdc ^{scid} /Rj mice with MDA-MB-231 breast cancer cells injection ^[1]	Dosage:	100 mg/kg	Administration:	Intravenous injection; 100 mg/kg once a week for 4 weeks	Result:	Significantly inhibited tumor growth in bones and breast cancer cell dissemination into other organs. Inhibited breast cancer-induced osteolytic lesions and subsequent loss of bone mass of the distal femur and of the proximal tibia. Redued phosphorylation of IKK α , IKK β , and p65.
Animal Model:	8-week-old female immune-compromised CB-17/lcr-Prkdc ^{scid} /Rj mice with MDA-MB-231 breast cancer cells injection ^[1]								
Dosage:	100 mg/kg								
Administration:	Intravenous injection; 100 mg/kg once a week for 4 weeks								
Result:	Significantly inhibited tumor growth in bones and breast cancer cell dissemination into other organs. Inhibited breast cancer-induced osteolytic lesions and subsequent loss of bone mass of the distal femur and of the proximal tibia. Redued phosphorylation of IKK α , IKK β , and p65.								

REFERENCES

[1]. Hesse E, et al. Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness. JCI Insight. 2019 Apr 9;5(9):e125543.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA